A new study led by investigators from Mass General Brigham shows that a brain waste- "clean-up" system is influenced by ...

Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes, may be a potential treatment for idiopathic intracranial hypertension (IIH). In a small phase 2 trial, ...

Please provide your email address to receive an email when new articles are posted on . AUSTIN, Texas — Venous manometry and neuroimaging may provide additional value when diagnosing patients who do ...

Int Ophthalmol Clin. 2014;54(1):27-41. Much of the data supporting weight loss as treatment for IIH comes from retrospective studies or class III evidence. There has been a long-standing need for ...

GLP-1 receptor agonists linked to lower medication use and reduced headaches, visual disturbances or blindness, and papilledema. (HealthDay News) — For patients with idiopathic intracranial ...

Glaucoma Drug, Plus Only 5-10 Percent Weight Loss Helps Restore Vision Loss to Patients with Idiopathic Intracranial Hypertension (IIH) National Institutes of Health (NIH)-Funded Study Published in ...

Please provide your email address to receive an email when new articles are posted on . Idiopathic intracranial hypertension has grown substantially in the U.S., particularly among young people and ...

If untreated, a disorder of high brain pressure called idiopathic intracranial hypertension can lead to vision loss. But this disorder can develop without noticeable symptoms, making it hard to catch.

Doctors think they've figured out a way to predict who might lose vision due to a high brain pressure disorder. Idiopathic intracranial hypertension occurs when there's unexplained pressure buildup in ...